07
Feb

Invictus Increases Investment In AB Laboratories

Investor Relations

Vancouver, BC, February 7, 2018 – INVICTUS MD STRATEGIES CORP. (“Invictus” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS1)is pleased to announce that the Company has completed the previously announced further strategic investment in the licensed production facility under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), AB Laboratories Inc. (“AB Labs”) located near Hamilton, Ontario, from its current 33.3% ownership interest to 50%.

Dan Kriznic, Chairman and CEO commented, “This is another significant milestone for Invictus. When we started this company in 2014 it was with the intention of becoming Canada’s Cannabis Company. AB Labs produces high quality strains, which will meet the increasing demand in the Canadian marketplace. Additionally we expect to receive a sales license for Acreage Pharms Ltd. (“Acreage Pharms”) within the first quarter of 2018.”

The terms of the investment include a direct cash investment in AB Labs of $10 million to be used for the expansion of AB Labs’ existing facility, acquisition of the land and building at the existing facility from the landlord, and for the acquisition of adjacent land and building as well as the retrofitting costs for that existing building (the “Secondary Facility”), for a combined production space of approximately 56,000 square feet. Invictus will make available to AB Labs a $2 million line of credit in the event costs exceed budget during the construction period.

Invictus’ license holders’ total annual kilogram capacity after various phases of expansion in 2018 and 2019, complete and in progress, is expected to be approximately 76,400 kg, based on expanding facilities in 2019 to approximately 520,000 square feet. The expected net production capacity to Invictus is approximately 67,000 kg after giving effect to the Invictus’ increased ownership of AB Labs to 50%. With the recent exercise of warrants and options, Invictus’ funded capacity today is approximately 27,200 kg.

Dan Kriznic, Chairman and CEO commented, “We continue to focus on utilizing our $38 million of cash in treasury to build out additional square footage to meet the expected demand once Canada becomes recreationally legal, which is anticipated this year. With our current funded capacity of approximately 27,200 kg and our additional planned expansion to get our license holders to approximately 76,400 kg in 2019 with a net to Invictus of 67,000 kg it would bring us in line with some of our peers that are leading the industry. The Sales license for AB Labs has been a catalyst to getting to this stage and the next catalyst will be our sales license for Acreage Pharms that is expected to occur in this first quarter of 2018.”

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on two main verticals within the Canadian cannabis sector, namely the Licensed Producers under the ACMPR, being its 100% investment in Acreage Pharms Ltd., located in West-Central Alberta, and 50% investment in AB Laboratories Inc., located near Hamilton, Ontario which has both its cultivation and sales license under ACMPR. Combined the two licenses and an expected third license under AB Ventures Inc. are expected to have an approximate annual run-rate production capacity of 76,400 kg by 2019. In addition to ACMPR licenses the Company has an 82.5% investment in Future Harvest Development Ltd. a Fertilizer and Nutrients manufacturer based in Kelowna, British Columbia.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
Dan Kriznic
Chairman & CEO

Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the potential production capacity of AB Labs, AB Ventures and Acreage Pharms’ production facilities, the granting of regulatory approval and anticipated timing of AB Labs reaching full production capacity, the granting of a sales license under the ACMPR to AB Ventures and Acreage Pharms, Acreage Pharms’ receipt of a sales license and the success and timing of Acreage Pharms’ expansion plans, expected sales of inventory, the successful consolidation of the property under the AB Labs ACMPR license  and the completion of the real property transactions contemplated by the investment agreement dated February 6, 2018 between the Company and AB Labs (the “Investment Agreement”) and the resulting increase in the Company’s ownership interest in AB Labs are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that AB Labs, AB Ventures and Acreage Pharms will satisfy all conditions for, and receive, regulatory approval to sell medical cannabis at their production facilities’ full capacity, AB Ventures will satisfy all conditions for and be granted a license under the ACMPR, AB Ventures is able to successfully build a production facility, Acreage Pharms will satisfy all conditions for and successfully obtain the anticipated sales license and will successfully complete its expansion plans, the anticipated sales of inventory will take place on the terms and timing expected by management, the consolidation of the property under the AB Labs ACMPR license will be successful and the real property transactions contemplated by the Investment Agreement will be satisfied and the transaction will complete on the expected terms. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that AB Labs, AB Ventures and Acreage Pharms will not receive regulatory approval to sell medical cannabis at their production facilities for their full production capacity or at all, that AB Labs, AB Ventures or Acreage Pharms will not reach full production capacity, that AB Ventures will not be granted a license under the ACMPR, that AB Ventures is not able to successfully build a production facility, that Acreage Pharms is not able to obtain the anticipated sales license when expected by management or at all or is not able to successfully complete its expansion plans, that the anticipated sales of inventory will not occur on the terms and timing expected by management or at all, that the real property transactions contemplated by the Investment Agreement will not complete on the expected terms or at all and the consolidation of the property under the AB Labs ACMPR license being unsuccessful. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Recent Posts

INVICTUS’ ACREAGE PHARMS COMPLETES SHIPMENT OF RECREATIONAL CANNABIS TO BRITISH COLUMBIA

September 25, 2018

Invictus provides update on German partnership and EU-GMP certification

September 24, 2018

Invictus Hires Ex-Heineken Executive Kevin Smith As VP Recreational Sales; Sarah Hardy As VP Medical Sales

September 17, 2018

Invictus Acreage Pharms To Become A Registered Cannabis Supplier In Saskatchewan

September 11, 2018
 

Categories

Archives

 September 2018
 August 2018
 July 2018
 June 2018
 May 2018
 April 2018
 March 2018
 February 2018
 January 2018
 December 2017
 November 2017
 October 2017
 September 2017
 August 2017
 July 2017
 June 2017
 May 2017
 April 2017
 March 2017
 February 2017
 January 2017
 December 2016
 November 2016
 October 2016
 August 2016
 March 2016
 February 2016
 December 2015
 November 2015
 October 2015
 September 2015

Download our Investor Deck





Download our Investor Deck